Información sobre riesgo, prevención, detección, síntomas, diagnosis, tratamiento y apoyo para el cáncer.
Información sobre el tratamiento del cáncer incluyendo quirúrgica, quimioterapia, radioterapia, estudios clínicos, terapia con protón, medicina complementaria avanzadas.
OncoLink se complace en ofrecer una amplia lista de lista completa de los agentes quimioterapéuticos más comúnmente usados??. Esta guía de referencia incluye información sobre la forma en que cada fármaco se administra, cómo funcionan, y los pacientes los efectos secundarios comunes pueden experimentar.
Maneras que los pacientes de cáncer y las personas que le cuidan puedan enfrentar el cáncer, los efectos secundarios, nutrición, cuestiones en general sobre el apoyo para el cáncer, duelo/decisiones sobre el termino de vida, y experiencias compartidas por sobrevivientes.
Tipos de Cancer / Cánceres del Hueso / Sarcoma de Ewing / Exámenes de Detección
National Cancer Institute®
Ultima Vez Modificado: 1 de marzo del 2002
1
UI - 11826016
AU - Takahashi M; Kahnoski R; Gross D; Nicol D; Teh BT
TI -
Familial adult renal neoplasia.
SO - J Med Genet 2002 Jan;39(1):1-5
AD - Laboratory of Cancer Genetics, Van Andel Research Institute, Grand
Rapids, MI 49503, USA.
Our understanding of the molecular mechanisms underlying the
tumorigenesis of renal cell carcinoma (RCC) has partially come from
studies of RCC related familial cancer syndromes such as von
Hippel-Lindau (VHL) disease and hereditary papillary RCC (HPRC). These
studies have led to the identification of RCC related genes, which,
besides allowing accurate diagnosis of these diseases, have been found
mutated or abnormally expressed in the sporadic counterparts of these
familial renal tumours. To date, a number of renal tumour related
syndromes have been described. We review recent advances in this field
and discuss a genetic approach to managing familial cases of renal
tumours occasionally encountered by cancer geneticists and urologists.
2
UI - 11688380
AU - Neumann HP; Riegler P; Huber W; Corradini R; Sessa A; Fontana D;
TI -
Wetterauer U; Janetschek G
The challenge of kidney lesions in von Hippel-Lindau disease.
SO - Contrib Nephrol 2001;(136):193-207
AD - Departments of Nephrology and Hypertension, Albert Ludwigs University,
Freiburg, Germany. Neumann@mm41.ukl.uni-freiburg.de
3
UI - 11723376
AU - Sims KB
TI -
Von Hippel-Lindau disease: gene to bedside.
SO - Curr Opin Neurol 2001 Dec;14(6):695-703
AD - Department of Neurology, Harvard Medical School, Massachusetts General
Hospital, 100 Blossom Street, Boston, MA 02114, USA.
sims@helix.mgh.harvard.edu
Von Hippel-Lindau is an autosomal dominant familial tumor syndrome with
a risk of developing central nervous system and retinal
hemangioblastomas, kidney cysts and clear cell carcinoma, cyst adenomas
of other organs and pheochromocytoma. Despite continued elaboration of
the neurobiologic role of the von Hippel-Lindau protein, the mainstay of
management remains the definitive clinical diagnosis of von
Hippel-Lindau syndrome (as distinct from sporadic cases of single von
Hippel-Lindau-associated tumors), clinical monitoring and preemptive
intervention by surgical or ablative therapy. Specific pharmacologic
treatment awaits further biologic understanding of critical pathogenic
components. Increasingly sensitive imaging and surgical techniques allow
for optimum clinical management and intervention. This article will
review von Hippel-Lindau molecular genetics, genotype-phenotype
correlations and clinical classification, current understanding of the
biology of the von Hippel-Lindau protein, its role in the
pathophysiology of this disorder and the consequent implications for
future therapeutic/interventional strategies. Central nervous system
manifestations will be highlighted.
The above citations and abstracts reflect those newly added to CANCERLIT for the month and topic listed in the title. The citations have been retrieved from CANCERLIT using a predefined search strategy of indexed subject terms. Although the search strategy has been refined as best as possible, citations may appear that are not directly related to the topic, and occasionally relevant references may be omitted.
What every person should know about screening, learning about your disease and the importance of cllinical research. Read more.
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Cladribine (2-CDA, Leustatin®)
Cyclophosphamide (Cytoxan®, Neosar®, Endoxan®)
Cyclosporine (Neoral®, Sandimmune®, Restasis®, Gengraf®)
Cytarabine (Cytosar-U®, Ara-C)
Irinotecan (Camptosar®, CPT-11)
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Men
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Women
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Busulfan (Myleran®, Busulfex®)
Intravesicular Mitomycin (Mutamycin®, Mitomycin-C, given into the bladder)
Mechlorethamine (Mustargen®, Nitrogen Mustard)
mechlorethamine, mustine, Mustargen®
Megestrol (Megace®, Megace-ES®)
Mercaptopurine (Purinethol®, 6-MP)
Methotrexate (Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX)
Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX
Mitomycin (Mutamycin®, Mitomycin-C)
Morphine Sulfate (Given by IV)
Morphine Sulfate (MS Contin®, Avinza®, Kadian®, Oramorph SR®)
MS Contin®, Avinza®, Kadian®, Oramorph SR®
Mutamycin®, Mitomycin-C, given into the bladder
Nitrogen mustard (mechlorethamine, mustine, Mustargen®)
Bendamustine Hydrochloride (Treanda®)
Bexarotene (Targretin®), Oral Formulation
Bexarotene Gel (Targretin® Gel Formulation)
Etoposide (Toposar®, VePesid®, Etopophos®,VP-16)
Thioguanine (6-TG, Thioguanine Tabloid®)
Toposar®, VePesid®, Etopophos®,VP-16
Trelstar LA® and Trelstar Depot®
Tretinoin (Vesanoid®, All-Trans-Retinoic Acid, ATRA)
Triptorelin (Trelstar LA® and Trelstar Depot®)

